Quiles M.G.,University of Sao Paulo |
Rocchetti T.T.,University of Sao Paulo |
Fehlberg L.C.,University of Sao Paulo |
Kusano E.J.U.,Laboratorio Diagnosticos da America |
And 5 more authors.
Brazilian Journal of Medical and Biological Research | Year: 2015
We report the microbiological characterization of four New Delhi metallo-β-lactamase-1 (blaNDM-1)-producing Enterobacteriaceae isolated in Rio de Janeiro, Brazil. blaNDM-1 was located on a conjugative plasmid and was associated with Klebsiella pneumoniae carbapenemase-2 (blaKPC-2) or aminoglycoside-resistance methylase (armA), a 16S rRNA methylase not previously reported in Brazil, in two distinct strains of Enterobacter cloacae. Our results suggested that the introduction of blaNDM-1 in Brazil has been accompanied by rapid spread, since our isolates showed no genetic relationship. © 2015, Associacao Brasileira de Divulgacao Cientifica. All rights reserved.
Lima G.A.B.,Federal University of Rio de Janeiro |
Lima G.A.B.,Instituto Estadual Of Diabetes E Endocrinologia Luiz Capriglione |
Wu Z.,Charité - Medical University of Berlin |
Silva C.M.S.,Federal University of Rio de Janeiro |
And 6 more authors.
Growth Hormone and IGF Research | Year: 2010
Background: Human growth hormone (hGH) circulates as a mixture of different isoforms. It has been previously reported that the ratio of 20. kDa to 20. kDa plus 22. kDa (%20. kDa-hGH) is increased in patients with active acromegaly. Objectives: To evaluate the GH isoforms (20. kDa- and 22. kDa-hGH) in acromegalic patients before and after six months of treatment with octreotide LAR, and to compare the results with those in healthy controls. In addition, the relationships between the %20. kDa-hGH, tumor size and biochemical measurements were also investigated. Design: Random serum samples from 23 acromegalic patients evaluated before and after six months of treatment with octreotide LAR and from 23 matched healthy controls were studied. Growth hormone, IGF-I and prolactin (PRL) were measured by chemiluminescence immunometric assay and the 20. kDa- and 22. kDa-hGH isoforms were measured by specific time-resolved fluorescence immunoassays. Results: In acromegalic patients before treatment, there was a significantly higher median %20. Da-hGH in comparison to healthy controls (14.31% vs 9.59%, p<0.001). After six months of treatment, the median %20. kDa-hGH was similar to the baseline values. Patients with GH. < 2.5. ng/mL after six months of treatment had already lower GH and %20. kDa-hGH at baseline (p<0.01). The IGF-I (SD-scores) was positively correlated to total GH levels in acromegalic patients after treatment. There was no correlation between the %20. kDa-hGH and PRL levels or tumor size. Conclusions: Our study confirmed that acromegalic patients have an increased proportion of circulating 20. kDa-hGH isoform. Consequently, the use of a 22. kDa-hGH specific assay may underestimate the tumor production of total GH. Although octreotide LAR promoted a significant decrease in the GH and IGF-I levels, it did not normalize the GH isoforms composition and suggests that the secretion of GH isoforms is equally inhibited by somatostatin analogues and that it is the disease control that normalizes the GH isoforms composition in acromegaly. © 2009 Elsevier Ltd.